Krystal Biotech vs Vericel
KRYS and VCEL side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How KRYS and VCEL compare
Krystal Biotech is the larger company, worth 3.0 times as much as Vericel ($8.8B against $2.9B).
On earnings, Krystal Biotech is cheaper: it trades at 37.3× trailing earnings, against 137× for Vericel.
Vericel grew revenue faster over the last twelve months (23.0% versus 22.6% for Krystal Biotech).
Krystal Biotech keeps more of each dollar of sales as profit, with a net margin of 54.8% compared with 7.9% at Vericel.
Vericel scores higher on the StockData Score (14 against 11 for Krystal Biotech), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | KRYS | VCEL |
|---|---|---|
| Size and price | ||
| Market cap | $8.8B | $2.9B |
| Share price | $297.90 | $57.48 |
| Change, 1 year | 48.1% | 44.3% |
| Change, 5 years | 648% | 50.0% |
| Beta (5Y) | 1.01 | −0.01 |
| Employees | 295 | 398 |
| StockData Score | ||
| Total score | 11 | 14 (better) |
| Valuation score | 1 (better) | 0 |
| Growth score | 1 | 4 (better) |
| Performance score | 3 | 4 (better) |
| Health score | 6 | 6 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 37.3× (better) | 137× |
| P/S | 20.0× | 9.6× (better) |
| P/B | 6.5× (better) | 8.0× |
| EV/EBITDA | 40.3× (better) | 89.3× |
| P/FCF | 34.2× (better) | 47.7× |
| FCF yield | 2.9% (better) | 2.1% |
| Fair value | $196.32 | $13.52 |
| Margin of safety | −51.7% (better) | −325% |
| Growth | ||
| Revenue growth (TTM) | 22.6% | 23.0% (better) |
| Revenue growth, 5Y average | – | 17.3% |
| Net income growth (TTM) | 64.6% | 241% (better) |
| EPS growth (TTM) | 62.2% | 500% (better) |
| EPS growth, 5Y average | – | 39.8% |
| Profitability | ||
| Gross margin | – | 74.6% |
| Operating margin | 44.9% (better) | 6.0% |
| Net margin | 54.8% (better) | 7.9% |
| FCF margin | 58.5% (better) | 20.1% |
| Return on equity | 20.1% (better) | 7.2% |
| Return on invested capital | 45.3% (better) | 7.2% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Interest coverage | – | 28.5× |
| Current ratio | 8.32 (better) | 5.04 |
| Altman Z-score | 38.98 (better) | 13.47 |
| Piotroski F-score | 6 | 7 (better) |
| Dividends and buybacks | ||
| Buyback yield | – | −0.24% |
| Shareholder yield | 0.00% (better) | −0.24% |
| Ownership | ||
| Held by institutions | 102% | 108% |
| Held by insiders | 17.1% | 1.3% |
| Insider net buying, 12 months | −$105M | −$13.0M (better) |
| Short interest, % of float | 12.4% | 10.6% |
Go deeper
- KRYS stock overview
- KRYS income statement
- KRYS valuation and score
- VCEL stock overview
- VCEL income statement
- VCEL valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.